Information Provided By:
Fly News Breaks for August 10, 2015
ABBV
Aug 10, 2015 | 09:03 EDT
Argus believes that AbbVie's strong Q2 results show that it has growth drivers other than Humira. The firm says that the company's Viekira Pak for hepatitis C and Imbruvica for blood cancers are "on track to become blockbuster products." The firm expects a number of the company's other key drugs to reach the market. It keeps an $85 price target and Buy rating on the shares.
News For ABBV From the Last 2 Days
There are no results for your query ABBV
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.